Fibrinogen gamma chain(FGG) Contains 2 sets of 3 non-identical chains (alpha, beta and gamma),A long coiled coil structure connects the central nodule to the C-terminal domains . The long C-terminal ends of the alpha chains fold back to contributing a fourth strand to the coiled coil structure.Defects in FGG are a cause of congenital afibrinogenemia (CAFBN) . CAFBN is a rare autosomal recessive disorder,it is characterized by bleeding that varies from mild to severe and by complete absence or extremely low levels of plasma and platelet fibrinogen.Patients with congenital fibrinogen abnormalities can manifest different clinical pictures,including tendency toward bleeding, clinically silent and predisposition for thrombosis with or without bleeding.

·Description
Novoprotein Recombinant Human Fibrinogen gamma chain/FGG produced by mammalian cells expression system.Target protein is expressed with sequence (M1-D130) of Human fgg (Uniprot #P02679) fused with a polyhistidine tag at the C-terminus.

·Quality Control

Purity: Greater than 90.0% as determined by:
(a) Analysis by RP-HPLC.
(b) Analysis by reducing and non-reducing SDS-PAGE Silver Stained gel.
 

Endotoxin:Less than 0.1ng/μg (1EU/μg) of Fibrinogen gamma chain/FGG (Human)

·Formulation
  Novoprotein Recombinant Human FGG was lyophilized at 1mg/ml in 20mM PBS.

·Reconstitution
We recommend a quick spin followed by reconstitution of Novoprotein Recombinant Human FGG in sterile 18MΩ-cm H2O not less than 100μg/ml, which can then be further diluted to working solutions.

·Storage
Lyophilized Recombinant Human FGG although stable at room temperature for 3 weeks, should be stored desiccated below -18°C. Upon reconstitution Recombinant Human FGG should be stored at 4°C between 2-7 days and aliquots of reconstituted samples are stable up to 3 months below -18°C for future use.

Please avoid freeze-thaw cycles.